Medizinische Hochschule Hannover

Klinik für Psychiatrie, Sozialpsychiatrie

und Psychotherapie


  • marckutschis

Studien Behandlung des Tourette-Syndroms mit dem neuen Medikament ABX-1431

First patient dosed in Phase 2 trial to evaluate the efficacy of ABX-1431 in treating adult patients with Tourette Syndrome

SAN DIEGO, October 16, 2018 — Abide Therapeutics, a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting the serine hydrolase family of enzymes, announced today the initiation of Phase 2 clinical development of ABX-1431, a first-in-class investigational monoacylglycerol lipase (MGLL) inhibitor, in patients with Tourette Syndrome (TS). TS is a neurodevelopmental disorder characterized by sudden, involuntary movements and vocal tics.  


38 Ansichten